Literature DB >> 7827478

Status epilepticus. A perspective from the neuroscience intensive care unit.

K G Jordan1.   

Abstract

Patients with GCSE and NCSE are common and may present to the emergency department or the NICU. In the NICU, NCSE is a more common presentation than GCSE. In the emergency department, GCSE commonly evolves to NCSE, either as a late sequela of prolonged SE or due to partial treatment with antiepileptic medication or neuromuscular blocking agents. In the emergency department, acute cerebral injuries are commonly found in patients presenting with SE, regardless of whether they have preexisting epilepsy. In the NICU, almost by definition, SE occurs in patients with acute cerebral injuries. Status epilepticus has been found to evolve sequentially through several stages, the end-point of which is a condition of refractory SE leading to neuronal necrosis and permanent cerebral injury. The responsiveness of SE to treatment is time-dependent. This makes early diagnosis and initiation of treatment essential. Most published treatment algorithms stress a 60-minute time window from the diagnosis of SE to its successful control. Unfortunately, the practical problem of patients with SE accessing such treatment protocols has been overlooked. Our preliminary (unpublished) data suggest that this access problem must be solved for treatment algorithms to improve the outcome of SE. In the NICU, access is less of a problem, and the determining factor is early diagnosis by NICU personnel. Because these patients usually sustain NCSE, which can be difficult to diagnose, a high index of suspicion and, optimally, continuous EEG monitoring are necessary for early diagnosis. NICU patients may be more susceptible to the ravages of SE because of their preexisting cerebral injuries. Expedited treatment may therefore be more important in this patient group. Clinical management of SE requires meticulous attention to ventilation and oxygenation, maintenance of adequate blood pressure, prevention of hyperthermia, and close monitoring for cardiac abnormalities. No specific medication is ideal for controlling SE. The knowledgeable and prompt use of intravenous lorazepam, a diazepam-phenytoin combination, or phenobarbital is acceptable as first-line treatment and as part of a systematic treatment algorithm. Refractory SE has been treated conventionally with high-dose intravenous barbiturate coma. Recent evidence suggests that high-dose intravenous midazolam may provide a useful alternative.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7827478

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  4 in total

1.  Management of status epilepticus in neurological versus medical intensive care unit: does it matter?

Authors:  Panayiotis N Varelas; Jesse Corry; Mohammed Rehman; Tamer Abdelhak; Lonni Schultz; Marianna Spanaki; James Bartscher
Journal:  Neurocrit Care       Date:  2013-08       Impact factor: 3.210

2.  Time from convulsive status epilepticus onset to anticonvulsant administration in children.

Authors:  Iván Sánchez Fernández; Nicholas S Abend; Satish Agadi; Sookee An; Ravindra Arya; James Nicholas Brenton; Jessica L Carpenter; Kevin E Chapman; William D Gaillard; Tracy A Glauser; Howard P Goodkin; Kush Kapur; Mohamad A Mikati; Katrina Peariso; Margie Ream; James Riviello; Robert C Tasker; Tobias Loddenkemper
Journal:  Neurology       Date:  2015-05-06       Impact factor: 9.910

3.  Identification and treatment of acute repetitive seizures in children and adults.

Authors:  James J Cereghino
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

4.  Refractory status epilepticus in children with and without prior epilepsy or status epilepticus.

Authors:  Iván Sánchez Fernández; Michele C Jackson; Nicholas S Abend; Ravindra Arya; James N Brenton; Jessica L Carpenter; Kevin E Chapman; William D Gaillard; Marina Gaínza-Lein; Tracy A Glauser; Joshua L Goldstein; Howard P Goodkin; Ashley Helseth; Kush Kapur; Tiffani L McDonough; Mohamad A Mikati; Katrina Peariso; James Riviello; Robert C Tasker; Alexis A Topjian; Mark S Wainwright; Angus Wilfong; Korwyn Williams; Tobias Loddenkemper
Journal:  Neurology       Date:  2016-12-23       Impact factor: 9.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.